148. Deputy Peter Burke asked the Minister for Health when osimertinib will be approved for reimbursement to replace tarceva for the treatment of patients with a specific type of lung cancer; if the HPRA has commissioned a review of the effectiveness of the new drug; if it will consider granting it to patients here in view of the relatively modest cost due to the small number of patients suffering with this specific form of lung cancer; if the Health Products Regulatory Authority, HPRA, and his Department have spoken to consultants here that are recommending their patients be treated with this drug; and if he will make a statement on the matter. [47050/19]

Summary

148. Deputy Peter Burke asked the Minister for Health when osimertinib will be approved for reimbursement to replace tarceva for the treatment of patients with a specific type of lung cancer; if the HPRA has commissioned a review of the effectiveness of the new drug; if it will consider granting it to patients here in view of the relatively modest cost due to the small number of patients suffering with this specific form of lung cancer; if the Health Products Regulatory Authority, HPRA, and his Department have spoken to consultants here that are recommending their patients be treated with this drug; and if he will make a statement on the matter. [47050/19]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Reimbursement

  xml · EN · 14 November 2019

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.